Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Neurotensin (NT) has emerged as an important modulator of nociceptive transmission and exerts its biological effects through interactions with 2 distinct GPCRs, NTS1 and NTS2. NT provides strong analgesia when administered directly into the brain; however, the blood-brain barrier (BBB) is a major obstacle for effective delivery of potential analgesics to the brain. To overcome this challenge, we synthesized chemical conjugates that are transported across the BBB via receptor-mediated transcytosis using the brain-penetrant peptide Angiopep-2 (An2), which targets LDL receptor-related protein-1 (LRP1). Using in situ brain perfusion in mice, we found that the compound ANG2002, a conjugate of An2 and NT, was transported at least 10 times more efficiently across the BBB than native NT. In vitro, ANG2002 bound NTS1 and NTS2 receptors and maintained NT-associated biological activity. In rats, i.v. ANG2002 induced a dose-dependent analgesia in the formalin model of persistent pain. At a dose of 0.05 mg/kg, ANG2002 effectively reversed pain behaviors induced by the development of neuropathic and bone cancer pain in animal models. The analgesic properties of ANG2002 demonstrated in this study suggest that this compound is effective for clinical management of persistent and chronic pain and establish the benefits of this technology for the development of neurotherapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man
Bennett, G. J., & Xie, Y.-K. (1988) · Pain · doi:10.1016/0304-3959(88)90209-6 · Cited by 5,376
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798 · cited 4×
“Functional characterization of the brain-to-blood efflux clearance of human amyloid-β peptide (1-40) across the rat blood-brain barrier.”
InfluentialDrug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994 · cited 6×
“To overcome the obstacle of drug delivery to the CNS, different strategies have been proposed to increase the transport of therapeutics from blood into brain parenchyma (5, 6).”
InfluentialCost of disorders of the brain in Europe 2010
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.008 · Cited by 1,723
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 1×
“…broad parenchymal distribution of ANG2002 was also observed for other An2 conjugates (12–16) or kunitz-derived peptides (7), likely reflecting the extraordinarily high density of cerebral capillaries (57) as well as the broad distribution of LRP1 throughout the brain-capillary tree (58, 59).”
Pardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191
Demeule, M., Currie, J., Bertrand, Y., Ché, C., Nguyen, T., Régina, A., Gabathuler, R., Castaigne, J., & Béliveau, R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05492.x · Cited by 557
Self-citationPhase I Study of GRN1005 in Recurrent Malignant Glioma
Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2481 · Cited by 190
Self-citationMahley, R. W., & Huang, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30889 · Cited by 159 · cited 5×
“Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential firstin-class analgesic.”
InfluentialPeptide therapeutics for CNS indications
McGonigle, P. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.10.014 · Cited by 95 · cited 1×
“Neuropeptides play a crucial role in regulation of the brain, and peptide receptors hold great promise in advancing structure-based drug discovery for the treatment of CNS disorders (49).”
Cited by
Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges
Pulgar, V. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01019 · Cited by 482
Blood–brain barrier shuttle peptides: an emerging paradigm for brain delivery
Oller-Salvia, B., Sánchez-Navarro, M., Giralt, E., & Teixidó, M. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00076b · Cited by 442
Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier
Lajoie, J. M., & Shusta, E. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124852 · Cited by 399
Advances in therapeutic peptides targeting G protein-coupled receptors
Davenport, A. P., Scully, C. C. G., de Graaf, C., Brown, A. J. H., & Maguire, J. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0062-z · Cited by 275
Kumthekar, P., Tang, S.-C., Brenner, A. J., Kesari, S., Piccioni, D. E., Anders, C., Carrillo, J., Chalasani, P., Kabos, P., Puhalla, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3258 · Cited by 250
Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier
Li, J., Zheng, M., Shimoni, O., Banks, W. A., Bush, A. I., Gamble, J. R., & Shi, B. (2021) · Advanced Science · doi:10.1002/advs.202101090 · Cited by 202
Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria
Haqqani, A. S., Bélanger, K., & Stanimirovic, D. B. (2024) · Frontiers in Drug Delivery · doi:10.3389/fddev.2024.1360302 · Cited by 153
Regina, A., Demeule, M., Tripathy, S., Lord-Dufour, S., Currie, J.-C., Iddir, M., Annabi, B., Castaigne, J.-P., & Lachowicz, J. E. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0399 · Cited by 112
Self-citationIsrael, L. L., Galstyan, A., Cox, A., Shatalova, E. S., Sun, T., Rashid, M.-H., Grodzinski, Z., Chiechi, A., Fuchs, D.-T., Patil, R., et al. (2022) · ACS Nano · doi:10.1021/acsnano.1c10034 · Cited by 41
Metadata
- Authors
- Demeule, M., Beaudet, N., Régina, A., Besserer-Offroy, É., Murza, A., Tétreault, P., Belleville, K., Ché, C., Larocque, A., Thiot, C., Béliveau, R., Longpré, J.-M., Marsault, É., Leduc, R., Lachowicz, J. E., Gonias, S. L., Castaigne, J.-P., & Sarret, P.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-02-17
- Volume
- 124
- Issue
- 3
- Pages
- 1199-1213
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2142845165
- Cited by
- 116
- References
- 10
- FWCI
- 5.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.